Pearl, which is now a member of the AstraZeneca Group, was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilising a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).
In 2007, Pearl began the development of leading product candidates with initial venture funding from 5AM Ventures, Clarus Ventures and New Leaf Ventures. In 2010, Vatera Healthcare Partners joined Pearl as a fourth investor. Between 2007-2013, Pearl’s four investors backed it with $167.5 million, allowing the progression of key therapeutic areas.
Subsequently, in 2013, AstraZeneca acquired Pearl to expand and strengthen its respiratory products portfolio, which includes many Pearl legacy compounds, and have made strides in bringing therapies to asthma patients.
Notably, Pearl’s lead combination medicine was recently launched in the US during the first quarter of 2017 and has regulatory submission acceptance in EU for COPD. Thanks to the Pearl team’s experience as inhalation product development experts, another lead product candidate is progressing through the pipeline as a potential treatment for COPD and asthma.
Pearl successfully delivered valuable therapeutics for a range of respiratory patients. As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.
AstraZeneca's Respiratory pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Respiratory (as at 24 October 2019)
Job Postings - Pearl
AstraZeneca's work environment is dynamic and fosters innovation. We believe where there's energy there's fulfilment and with jobs from Cambridge, UK to Shanghai, China we've got the role for you.